IRVINE, Calif., May 11, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, reported today that total revenues for the first quarter of 2011 increased 11% to $913,000 from $820,000 in the first quarter of 2010. First quarter 2011 revenues were generated exclusively from the delivery of diagnostic testing services, compared to diagnostic test services revenues of $772,000 and array CGH revenues of $48,000 during the first quarter of 2010, representing an 18% increase in diagnostic test services revenues for the 2011 period. In comparison to the fourth quarter of 2010, diagnostic testing services revenues increased sequentially by 15% from $791,000.
